CRISPR Therapeutics AG Files 8-K Report
Ticker: CRSP · Form: 8-K · Filed: May 19, 2025 · CIK: 1674416
Sentiment: neutral
Topics: material-definitive-agreement, corporate-disclosure, financial-statements
Related Tickers: CRSP
TL;DR
CRISPR Therapeutics filed an 8-K on 5/19/25 covering material agreements and other events.
AI Summary
On May 19, 2025, CRISPR Therapeutics AG filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/exhibits. The company is incorporated in Switzerland and its principal executive offices are located in Zug.
Why It Matters
This 8-K filing indicates significant corporate activity, potentially related to new agreements or financial updates, which could impact investors and the company's strategic direction.
Risk Assessment
Risk Level: low — This filing is a standard corporate disclosure and does not inherently present new risks.
Key Numbers
- 001-37923 — SEC File Number (Identifies the company's filing history with the SEC.)
Key Players & Entities
- CRISPR Therapeutics AG (company) — Registrant
- May 19, 2025 (date) — Date of earliest event reported
- Switzerland (location) — State of Incorporation
- Zug (location) — Address of Principal Executive Offices
FAQ
What is the nature of the material definitive agreement mentioned in the 8-K filing?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.
What other events are reported in this 8-K filing?
Besides the material definitive agreement, the filing also reports 'Other Events' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on May 19, 2025.
Where are CRISPR Therapeutics AG's principal executive offices located?
The principal executive offices are located at Baarerstrasse 14, 6300 Zug, Switzerland.
What is the company's SEC file number?
The SEC file number for CRISPR Therapeutics AG is 001-37923.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 19, 2025 regarding CRISPR Therapeutics AG (CRSP).